[Visual prognosis and patient selection].
Choroidal neovascularization (CNV) is one of the leading causes of central vision loss. Laser photocoagulation and photodynamic therapy may reduce the risk of severe loss of visual acuity in subfoveal CNV secondary to age-related macular degeneration. However, the most favorable effect of these therapies is the slowing of the vision loss. Macular translocation surgery, removing the neurosensory retina away from the area of choroidal neovascularization to a healthier underlying tissue, may improve or stabilize the visual acuity. Several pilot studies of this surgery reported visual recovery in selected patients. Well-designed, controlled randomized studies are needed to clarify the role of the macular translocation surgery in treatment of choroidal neovascularization. Given the severe complications of this surgery, it is of utmost importance to discuss the potential risks and advantages of this procedure with the patient.
Gelisken
F
F
Universitäts-Augenklinik Tübingen, Abteilung I, Schleichstrasse 12, 72076 Tübingen. Faik.Gelisken@med.uni-tuebingen.de
Bartz-Schmidt
K U
KU
D020256:Choroidal Neovascularization / Q000150:complications; D005500:Follow-Up Studies; D006801:Humans; D017075:Laser Coagulation; D008266:Macula Lutea / Q000601:surgery*; D008268:Macular Degeneration / Q000188:drug therapy / Q000209:etiology / Q000601:surgery*; D015337:Multicenter Studies as Topic; D013508:Ophthalmologic Surgical Procedures; D018579:Patient Selection; D010778:Photochemotherapy; D017319:Photosensitizing Agents / Q000008:administration & dosage / Q000627:therapeutic use; D010865:Pilot Projects; D011166:Porphyrins / Q000008:administration & dosage / Q000627:therapeutic use; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D013997:Time Factors; D000077362:Verteporfin
D017319:Photosensitizing Agents; D011166:Porphyrins; D000077362:Verteporfin
Visusprognose und Patientenselektion.